Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MK0966, rofecoxib · 8 trials · 3 indications
| Name | Type | Description |
|---|---|---|
| MK0966, rofecoxib | DRUG | - |
| Comparator: diclofenac sodium, placebo | DRUG | - |
| Comparator: celecoxib, placebo | DRUG | - |
| Comparator: valdecoxib, placebo | DRUG | - |
| Comparator: oxycodone and acetaminophen | DRUG | - |
| Comparator: oxycodone with acetaminophen, placebo | DRUG | - |
| Comparator: valdecoxib | DRUG | - |
| MK0966 / Duration of Treatment: 1 Days | DRUG | - |
| Comparator: acetaminophen (+) hydrocodone bitartrate / Duration of Treatment: 1 Days | DRUG | - |
| Comparator: placebo (unspecified) / Duration of Treatment: 1 Days | DRUG | - |
Inclusion Criteria: * Bunion removal Exclusion Criteria: * Any known allergies to the study design
Top 5 of 13 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Eli Lilly and Company | LLY | 3 | PHASE3 | Eloralintide and Tirzepatide, Orforglipron, LY3016859, LY3556050, LY3526318 |
| Pacira Biosciences, Inc. | PCRX | 4 | PHASE3 | ZILRETTA, Enekinragene Inzadenovec, FX201 |
| Novo Nordisk A/S Sponsored ADR Class B | NVO | 1 | PHASE3 | NNC0487-0111 |
| Bioventus, Inc. Class A | BVS | 1 | PHASE2 | PTP-001 |
| Enlivex Ltd. | ENLV | 2 | PHASE1 | Allocetra |
MK0966, also known as rofecoxib, was studied for osteoarthritis, postoperative pain, and pain following arthroscopic surgery. Its clinical program covered musculoskeletal pain conditions, including post-bunionectomy surgery pain. The trials enrolled adults, with osteoarthritis studies requiring participants aged 40 years and older.
Rofecoxib, also called MK0966, was developed by Merck & Company, Inc., which trades under the ticker MRK. Merck sponsored the clinical trial program evaluating the drug across osteoarthritis and postoperative pain indications.
MK0966 (rofecoxib) reached Phase 3 clinical development. Five Phase 3 trials were conducted, all of which are now completed, with no active trials ongoing. The studies together enrolled approximately 1,366 participants.
Rofecoxib was evaluated in five completed Phase 3 trials, including NCT00390260 in pain following arthroscopic surgery, NCT00092378 in post-bunionectomy surgery pain, and NCT00092365 and NCT00092352 in osteoarthritis. These randomized, double-blind studies enrolled adults aged 18 years and older, or 40 years and older for osteoarthritis.
Yes, MK0966 and rofecoxib refer to the same compound. Merck & Company, Inc. developed it under the MK0966 designation, and it is also identified in trial records as MK0966 with a one-day duration of treatment. Searches for either name refer to the same drug candidate.